Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 1.643
Filtrar
1.
Int. j. morphol ; 38(1): 43-47, Feb. 2020. tab, graf
Artigo em Inglês | LILACS | ID: biblio-1056395

RESUMO

Rheumatoid arthritis (RA) is a disease triggered by environmental and genetic factors. Research suggests that physical exercise has benefits such as delaying functional disability. In vivo studies using experimental models of arthritis can provide useful information about these benefits. to analyze the effects that different intensities of aquatic physical exercise have on the proprieties of the bones in induced arthritis in knees of Wistar rats. Male Wistar adults rats (n=20) were divided into 5 groups: Group Control Arthritis (GCA) n=4, Group control Placebo (GCP) n=4, Group Low Physical Activity (GB) n=4, Group Moderate Physical Activity (GM) n=4 and Group Intense Physical Activity (GI) n=4. The physical activity groups got an intra-articular injection of Zymosam on the right knee; the GCA received saline solution in the right knee; the GCP was submitted to the stress of the needle. The animals were submitted to aquatic activity for 30 minutes, 4 times a week for 5 weeks, and the intensity of the exercise was determined by a weight placed on their back: GB=1 %, GM=5 %, GI=15 % of their body weight. It was observed that the group GB, and the groups that did not exercise GCA and GCP, gained more weight compared to the group GM. In relation to the bone mineral content of the tibia, there was a decrease in the GM group when compared to the GCP group, whereas in the tibial bone mineral density there was a decrease in the GM group compared to the GCP, GCA, GB. As for the area of the femur, the GI group presented an increase of it compared to the GB and GM groups. It is concluded that the high intensity exercises promote better results in bone properties.


La investigación sugiere que el ejercicio físico tiene beneficios como retrasar la discapacidad funcional de la artritis reumatoide. Los estudios in vivo que utilizan modelos experimentales de artritis pueden proporcionar información útil sobre estos beneficios. Se analizaron los efectos de las intensidades del ejercicio físico acuático sobre las propiedades de los huesos, en la artritis inducida en las rodillas de ratas Wistar. Las ratas Wistar macho adultas (n = 20) se dividieron en 5 grupos: grupo de control artritis (ACG) n = 4, grupo control placebo (CGP) n = 4, grupo de actividad física baja (GB) n = 4, grupo de actividad física moderada (GM) n = 4 y grupo de actividad física intensa (GI) n = 4. Los grupos de actividad física recibieron una inyección intraarticular de Zymosam en la rodilla derecha; el GCA recibió solución salina en la rodilla derecha; el CGP fue sometido a la tensión de una aguja. Los animales fueron sometidos a actividad acuática durante 30 minutos, 4 veces a la semana durante 5 semanas, y la intensidad del ejercicio se determinó mediante un peso colocado sobre su espalda: GB = 1 %, GM = 5 %, GI = 15 % de su peso corporal. Se observó que el grupo GB, y los grupos que no ejercitaron GCA y CGP, ganaron más peso en comparación con el grupo GM. En relación con el contenido mineral óseo de la tibia, hubo una disminución en el grupo GM en comparación con el grupo GCP, mientras que en la densidad mineral del hueso tibial hubo una disminución en el grupo GM en comparación con el GCP, GCA, GB. En cuanto al área del fémur, el grupo GI presentó un aumento en comparación con los grupos GB y GM. En conclusión el ejercicio de alta intensidad promueve mejores resultados en las propiedades óseas.


Assuntos
Animais , Masculino , Ratos , Artrite Reumatoide/patologia , Natação/fisiologia , Tíbia/patologia , Fêmur/patologia , Artrite Reumatoide/fisiopatologia , Tíbia/fisiopatologia , Peso Corporal , Exercício Físico/fisiologia , Ratos Wistar , Modelos Animais de Doenças , Fêmur/fisiopatologia
2.
Fisioter. Mov. (Online) ; 33: e003319, 2020. tab, graf
Artigo em Inglês | LILACS | ID: biblio-1090395

RESUMO

Abstract Introduction: Rheumatoid arthritis (RA) is a progressive disease that causes deformation and constant joint damage. Handgrip strength (HGS) has been used by several health professionals in clinical practice as a mechanism for assessing muscle strength and overall performance. Objective: To perform the concordance analysis of handgrip strength measurements using a pneumatic dynamometer (Bulb) and a hydraulic dynamometer (Jamar) in women with rheumatoid arthritis. Method: The HGS measurements by the two dynamometers followed the norms of the American Society of Hand Therapists. The concordance between measurements was performed by the Bland-Altman method. Significance level was 5%. Results: In total, 41 women (60.63 ± 8.35 years) participated in the study. Analysis showed that the measures between the two dynamometers were not concordant (bias = 9.04, p < 0.01), there was a linear relationship between the difference of the measures and the mean (r = 0.73, p < 0.01), and the limits of agreement were very extensive (−2.74 to 20.81). Conclusion: Assuming that the rheumatoid arthritis compromises the hands, with a consequent decrease in HGS, further exploration of the subject is suggested in future studies to define the best measure for clinical practice at the different levels of health care. However, since there are many different dynamometers, we suggest to better explore the agreement between the measurements obtained by them in populations under different conditions.


Resumo Introdução: Artrite reumatóide (AR) é uma doença progressiva que causa deformação e comprometimento articular. A força de preensão palmar (FPP) tem sido usada por vários profissionais de saúde, na prática clínica, para avaliar força muscular e desempenho. Objetivo: Analisar a concordância das medidas de força de preensão palmar usando o dinamômetro pneumático (Bulbo) e hidráulico (Jamar) em mulheres com artrite reumatoide. Método: As medidas de FPP pelos dois dinamômetros seguiram as normas da American Society of Hand Therapists. A concordância entre as medidas foi por meio do método de Bland-Altman. Nível de significância de 5%. Resultados: Participaram 41 mulheres (60,63 ± 8,35 anos). A análise entre os dois dinamômetros demonstrou não haver concordância (bias = 9,04, p < 0,01), com uma relação linear entre a diferença das medidas e a média (r = 0,73, p < 0,01) e, os limites de concordância foram muito extensos (-2,74 to 20,81). Conclusão: Como a artrite reumatoide compromete as mãos com consequente diminuição da FPP, é importante explorar melhor este tema para definir a melhor medida para a prática clínica nos diferentes níveis de atenção à saúde. No entanto, devido ao grande número de tipo de dinamômetros, sugere-se novos estudos sobre a concordância destas medidas em populações de diferentes condições.


Resumen Introducción: La artritis reumatoide (AR) es una enfermedad progresiva que causa deformación y compromiso articular. La fuerza de prensión palmar (FPP) ha sido utilizada por varios profesionales de la salud, en la práctica clínica, para evaluar la fuerza muscular y el rendimiento. Objetivo: Analizar la concordancia de las medidas de fuerza de prensión palmar usando el dinamómetro neumático (Bulbo) e hidráulico (Jamar) en mujeres con artritis reumatoide. Método: Las medidas de FPP por los dos dinamómetros siguieron las normas de la American Society of Hand Therapists. La concordancia entre las medidas fue mediante el método de Bland-Altman. Nivel de significancia del 5%. Resultados: Participaron 41 mujeres (60,63 ± 8,35 años). El análisis entre los dos dinamómetros demostró no haber concordancia (bias = 9,04, p < 0,01), con una relación lineal entre la diferencia de las medidas y la media (r = 0,73, p < 0,01), los límites de concordancia fueron muy extensos (-2,74 a 20,81). Conclusión: Como la artritis reumatoide compromete las manos con consecuente disminución de la FPP, es importante explorar mejor este tema para definir la mejor medida para la práctica clínica en los diferentes niveles de atención a la salud. Sin embargo, debido al gran número de dinamómetros, se sugiere nuevos estudios sobre la concordancia de estas medidas en poblaciones de diferentes condiciones.


Assuntos
Feminino , Artrite Reumatoide , Dinamômetro de Força Muscular , Força Muscular , Articulações
3.
Rev. am. med. respir ; 19(3): 248-250, set. 2019. ilus, tab
Artigo em Espanhol | LILACS | ID: biblio-1041710

RESUMO

La artritis reumatoide (AR) es una enfermedad autoinmune de causa desconocida y de evolución crónica que afecta fundamentalmente a las articulaciones provocando una sinovitis erosiva crónica y simétrica, presenta muchas complicaciones extraarticulares, siendo la patología pleural la complicación más frecuente entre las neumológicas. El síndrome de Contarini1 es una entidad infrecuente que consiste en la existencia concomitante de derrames pleurales bilaterales de diferente etiología. Presentamos el caso de un paciente en el que coincidieron ambas condiciones patológicas


Assuntos
Derrame Pleural , Artrite Reumatoide
4.
J. bras. econ. saúde (Impr.) ; 11(2): 105-111, Agosto/2019.
Artigo em Inglês | LILACS, ECOS | ID: biblio-1021033

RESUMO

Objective: To perform a cost-minimization analysis comparing the cohort with the current average patient weight of 70 kg (MoH current assumption). Since most rheumatoid arthritis (RA) patients in Brazil are women (60 kg or less), we also aimed to define this percentage at Brazilian public healthcare system (SUS). Methods: Treatment-naïve RA patients using biologics from January 2008 to November 2018 were retrieved from Datasus as well as the number of patients ≤ 60 kg and their drug use distribution. Data on drug costs were assessed from the last payment reported by MoH and then recalculated using the weighted average of 60 kg and a 52-weeks a year to assess cost-minimization. Results: In the studied cohort, 33,646 patients (33.3%) were classified as ≤ 60 kg. Annual cost per patient, considering an average weight of 60 kg, ranged from 2,872,29 USD to 4,223.93 USD. Tocilizumab 80 mg was the only drug demonstrating a reduction in annual cost per patient (-526.79 USD). Conclusion: Cost-minimization analysis based on weight-dependent dosage showed that tocilizumab could reduce MoH costs with RA treatment in 14.28%. By adopting weight-dependent dose of 60 kg, the Brazilian government could save up to 916,651.31 USD per year using tocilizumab versus other biological disease-modifying antirheumatic drugs (DMARDs). In ten years, it represents an accumulative saving of 9,166,513.57 USD.


Objetivo: Realizar uma análise de custo-minimização comparando a coorte com o peso médio de pacientes de 70 kg (atual premissa do Ministério da Saúde ­ MS). Como a maioria dos pacientes são mulheres (≤ 60 kg), também se objetivou definir esse percentual no sistema público de saúde brasileiro (SUS). Métodos: Pacientes com artrite reumatoide (AR) virgens de tratamento utilizando biológicos de janeiro/2008 a novembro/2018 foram retirados do Datasus, assim como o número de pacientes com ≤ 60 kg e a distribuição de uso das drogas. Os custos dos medicamentos foram avaliados a partir do último pagamento relatado pelo MS e recalculados utilizando a média de 60 kg e um ano de 52 semanas para estimar a custo-minimização. Resultados: Na coorte estudada, 33.646 pacientes (33,3%) foram classificados com ≤ 60 kg. O custo anual por paciente, considerando o peso médio de 60 kg, variou de 2.872.29 a 4.223,93 USD. Tocilizumabe 80 mg foi o único que demonstrou redução no custo anual por paciente (-526,79 USD). Conclusão: A custo-minimização baseada em dose peso-dependente mostrou que o tocilizumabe poderia reduzir os custos do MS no tratamento de AR em 14,28%. Ao adotar o peso de 60 kg, o governo poderia economizar até 916.651,31 USD ao ano utilizando tocilizumabe vs. outros medicamentos modificadores do curso da doença biológicos (MMCDb). Em 10 anos, isso representa uma economia acumulada de 9.166.513,57 USD.


Assuntos
Humanos , Artrite Reumatoide , Sistema Único de Saúde , Custos e Análise de Custo
5.
J. bras. econ. saúde (Impr.) ; 11(2): 119-127, Agosto/2019.
Artigo em Português | LILACS, ECOS | ID: biblio-1021058

RESUMO

Objetivo: O Planserv oferece cobertura à terapia biológica para as patologias de artrite reumatoide (AR), espondilite anquilosante (EA) e artrite psoriática (AP). Em agosto de 2016, 78 pacientes estavam em uso do medicamento Remicade® (infliximabe). Nessa data, o valor do Remicade® foi reduzido para o mesmo valor do Remsima™ (infliximabe biossimilar). Com isso, todos pacientes que estavam usando o Remicade® trocaram por Remsima™. Conduzimos um estudo para medir a descontinuidade da terapia e a economia. Métodos: Estudo de mundo real (coorte prospectiva), não controlado, em pacientes com AR, AP e EA que estavam utilizando Remicade® e trocaram para Remsima™, entre setembro de 2016 e setembro de 2017. O desfecho primário foi o índice de descontinuidade do tratamento (por qualquer causa). O desfecho secundário foi a taxa de "aumento da atividade da doença", medida por meio dos escores SDAI, BASDAI e CASPAR. Foi considerado como "aumento da atividade da doença" qualquer medida superior à medida inicial e que estivesse acima do limite de remissão da doença. Os valores de referência para "aumento da atividade da doença" foram as medidas históricas. O impacto econômico foi medido por uma análise de custo-minimização. Resultados: Em setembro de 2017, 5 (6%) pacientes que realizaram a troca do Remicade® para o Remsima™, descontinuaram a terapia (4 por falhas e 1 perda de acompanhamento). A taxa de descontinuação de referência (Remicade®) foi de 11% (9% de falha e 2% por perda de acompanhamento). As análises de subgrupo (descontinuidade da terapia por tipo de patologia) foram equivalentes. A taxa de "aumento da atividade da doença" ocorreu em 42% dos pacientes para o Remsima™ e em 46% para o Remicade®. As análises de subgrupo (por tipo de patologia) também demonstraram que as taxas de aumento da atividade da doença foram semelhantes entre os grupos. A análise econômica mostrou que a mudança do Remicade® para o Remsima™ trouxe economia de R$ 1,75 milhão de reais (0,5 milhão de dólares), com 1.689 ampolas de infliximabe dispensadas no período. Conclusão: A troca do medicamento Remicade® pelo Remsima™ nos pacientes com AR, EA e AP, no contexto do Planserv, demonstrou ter sido uma medida segura, eficaz e econômica.


Objective: Planserv offers coverage of biological therapy for rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PA). In August 2016, 78 patients were on Remicade® (infliximabe). At this date the value of Remicade® was reduced to the same value as Remsima™ (infliximabe biossimilar), with this all patients who were using Remicade® exchanged for Remsima™. We conducted a study to measure therapy discontinuity, and economics. Methods: An uncontrolled real-world study (prospective cohort) these patients who were using Remicade® and switched to Remsima™ between September 2016 and September 2017. The primary outcome was the discontinuation rate of treatment (for any cause). The secondary outcome was the "increased disease activity" rate as measured by the scores SDAI, BASDAI and CASPAR. It was as "increased disease activity", any measure higher than the initial, and that was above the remission limit of the disease. The reference values for "increased disease activity" were the historical measures. The economic impact measured by a cost minimization analysis. Results: In September 2017, 5 (6%) patients who switched from Remicade® to Remsima™, discontinued therapy (4 due to failure and 1 loss of follow-up). The reference discontinuation rate (Remicade®) was 11% (9% failure and 2% loss of follow-up). Subgroup analyzes (discontinuation of therapy by type of pathology) were equivalent. The rate of "increased disease activity" occurred in 42% of patients for Remsima™, and 46% for Remicade®. Subgroup analyzes (by type of pathology) also showed that rates of increase in disease activity were similar between groups. The economic analysis showed that the change from Remicade® to Remsima™ savings of R $ 1.75 million (US $ 0.5 million), with 1,689 ampoules of infliximabe dispensed in the period. Conclusion: The switching of Remicade® by Remsima™ in patients with RA, SA and PA in the context of Planserv, has been shown to be a safe, effective and economical measure.


Assuntos
Humanos , Artrite Reumatoide , Espondilite Anquilosante , Artrite Psoriásica , Medicamentos Biossimilares , Infliximab
6.
Rev. argent. reumatol ; 30(2): 5-10, jun. 2019. ilus, tab
Artigo em Espanhol | LILACS | ID: biblio-1041880

RESUMO

La depresión es una de las comorbilidades más frecuentemente reportadas en pacientes con Artritis Reumatoidea (AR). Su presencia se asocia a mayores costos de salud, mayor mortalidad y reduce las probabilidades de alcanzar una buena respuesta al tratamiento. Objetivo: Evaluar la prevalencia de depresión en pacientes argentinos con AR y establecer su relación con diferentes factores sociodemográficos y clínicos. Material y métodos: Se incluyeron pacientes ≥18 años de edad, con diagnóstico de AR según criterios ACR-EULAR 2010. Se consignaron datos sociodemográficos, comorbilidades, características clínicas, actividad de la enfermedad y tratamiento actual. Se administraron los cuestionarios EQ-5D-3L, QOL-RA, HAQ-A y PHQ-9. Los valores de PHQ-9 de 5-9, 10-14, 15-19 y ≥20 determinan la presencia de depresión leve, moderada, moderada/severa y severa, respectivamente y un valor de corte ≥10, depresión mayor. Análisis estadístico: Test T de Student, ANOVA y Chi². Regresión lineal múltiple. Resultados: Se incluyeron 258 pacientes, con un tiempo mediano (m) de evolución de la enfermedad de 9 años (RIC 3,6-16,7). La m de depresión valorada por PHQ-9 de 6 (RIC 2-12,5). La prevalencia de depresión mayor fue de 33,8%. Sesenta y seis (25,6%), 42 (16,3%), 27 (10,5%) y 18 (7%) pacientes presentaron depresión leve, moderada, moderada/severa y severa, respectivamente. Los pacientes con depresión mayor mostraron menor capacidad funcional (HAQ-A X1,6±0,8 vs X0,7±0,7, p <0,0001), peor calidad de vida (QOL-RA X5,4±1,8 vs X7,3±1,6, p <0,0001), más dolor (EVN X56,2±27,5 mm vs X33,4±25,7 mm, p <0,0001), mayor actividad de la enfermedad (DAS28-ERS X4,3±1,4 vs X3,3±1,3, p <0,0001), mayor frecuencia de desempleo (71% vs 29%, p=0,015 ) y de comorbilidades (67% vs 33%, p=0,017) y menor frecuencia de actividad física (22% vs 35%, p=0,032). En el análisis multivariado, peor capacidad funcional (OR: 2,1, IC 95%: 1,6-4,3, p <0,0001) y calidad de vida (OR: 0,7, IC 95%: 0,5-0,8, p <0,0001) se asociaron independientemente a la presencia de depresión mayor. Conclusiones: La prevalencia de depresión mayor medida por PHQ-9 en esta cohorte argentina de pacientes con AR fue de 33,8%. La presencia de depresión tiene un impacto negativo sobre la capacidad funcional y la calidad de vida de estos pacientes, independientemente de la actividad de la enfermedad.


Depression is one of the most frequent comorbidity in patients with Rheumatoid Arthritis (RA). It's presence is associated with higher healthcare costs, mortality rate and reduced odds of achieving a good treatment response. Objective: To determine the prevalence of depression in Argentinean patients with RA and to establish its relationship with different sociodemographic and clinical factors. Material and methods: Consecutive patients ≥18 years old, with a diagnosis of RA according to ACR-EULAR 2010 criteria were included. Sociodemographic data, comorbidities, RA characteristics, disease activity and current treatment were registered. Questionnaires were administered: EQ-5D-3L, QOL-RA, HAQ-A and PHQ-9. PHQ-9 scores of 5-9, 10-14, 15-19, ≥20 represent mild, moderate, moderate/severe and severe depression, respectively and a cut-off value ≥10, major depression. Statistical analysis: Student's T, ANOVA and Chi² tests. Multiple logistic regression. Results: 258 patients were included, with a median (m) disease duration of 9 years (IQR 3.6-16.7). The m PHQ-9 score was 6 (IQR 2-12.3). The prevalence of major depression was 33.8%. 66 (25.6%), 42 (16.3%), 27 (10.5%) and 18 (7%) patients presented mild, moderate, moderate/severe and severe depression, respectively. Patients with mayor depression had worse functional capacity (HAQ-A X 1.6±0.8 vs X 0.7±0.7, p <0.0001), poorer quality of life (QOL-RA X 5.4±1.8 vs X 7.3±1.6, p <0.0001), greater pain (NVS X 56.2±27.5 mm vs X 33.4±25.7 mm, p <0.0001), higher disease activity (DAS28-ESR X 4.3±1.4 vs X 3.3±1.3, p <0.0001), higher frequency of unemployment (71% vs 29%, p=0.015 ) and comorbidities (67% vs 33%, p=0.017) and lower frequency of physical activity (22% vs 35%, p=0.032). In the multivariate analysis, patients with moderate and severe depression had worse functional capacity (OR: 2.1, 95% CI: 1.6-4.3, p <0.0001) and quality of life (OR: 0.7, 95% CI: 0.5-0.8, p <0.0001), independently of disease activity. Conclusion: The prevalence of mayor depression in this Argentinean cohort of patients with RA was 33.8%. The presence of depression had a negative impact on functional capacity and quality of life regardless of disease activity.


Assuntos
Artrite Reumatoide , Depressão
7.
Rev. argent. reumatol ; 30(2): 13-17, jun. 2019. graf, tab
Artigo em Espanhol | LILACS | ID: biblio-1041881

RESUMO

Introducción: Metotrexato (MTX) es la medicación más utilizada en pacientes con Artritis Reumatoidea (AR). Sin embargo, varios autores han cuestionado su éxito debido a la frecuente presencia de eventos adversos y la consiguiente falta de adherencia al tratamiento. Objetivos: Determinar la sobrevida al tratamiento con MTX, eventos adversos y causas de discontinuación en pacientes con AR. Material y métodos: Se incluyeron pacientes ≥18 años de edad con diagnóstico de AR (criterios ACR/EULAR 2010), en forma consecutiva, que hubiesen iniciado en algún momento tratamiento con MTX. Se consignaron datos sociodemográficos, clínicos y terapéuticos. Se determinó fecha de inicio y suspensión de MTX, forma de administración, tratamientos concomitantes, consumo de café y tabaco, como también presencia de eventos adversos (EA). La adherencia se evaluó utilizando el cuestionario Compliance Questionnaire Rheumatology de 5 ítems (CQR5). Análisis estadístico: Estadística descriptiva. Test Chi² o test exacto de Fisher. Sobrevida del tratamiento por Kaplan-Meier y log Rank. Regresión logística múltiple. Una p <0,05 se consideró significativa. Resultados: Se incluyeron 118 pacientes, 101 mujeres (85,6%), con una edad mediana (m) de 56 años (RIC 49-64) y tiempo m de evolución de 10 años (RIC 6-18). Ochenta y cinco pacientes (72%) recibieron MTX por vía oral. 43,2% presentaron EA asociados al MTX, donde solo 20 pacientes (16,9%) tuvieron que discontinuar. La intolerancia digestiva fue el EA más frecuente (27,1%), seguida por alteraciones del laboratorio (12,7%). 86,6% de los pacientes presentaron una adherencia ≥80%. La supervivencia mediana acumulada del tratamiento con MTX fue de 348 meses (IC 95%: 235-460,9). En los análisis uni y multivariados no se encontró asociación de la sobreviva del MTX con variables sociodemográficas, características de la enfermedad, tratamiento concomitante, vía de administración, consumo de café y nivel de adherencia. Conclusión: En nuestra cohorte, la adherencia y sobrevida del tratamiento con MTX fueron buenas. La sobrevida acumulada fue de casi 30 años. La presencia de EA no determinó la suspensión del tratamiento en la mayoría de los casos.


Background: Methotrexate (MTX) is the most frequently used medication in patients with Rheumatoid Arthritis (RA). However, several authors have questioned its success due to the presence of adverse events and the lack of adherence. Objectives: To determine cumulative survival of MTX, frequency and type of adverse events and causes of discontinuation in patients with RA. Methods: Consecutive patients 18 years and older with a diagnosis of RA (ACR/EULAR 2010 criteria), who had begun treatment with MTX during their disease were included. Sociodemographic, clinical and therapeutic data were collected. Date of initiation and suspension of MTX, route of administration, concomitant treatments, consumption of coffee and tobacco, presence of adverse events (AE) were all consigned. Adherence was evaluated using the Compliance Questionnaire Rheumatology questionnaire 5-item summary version (CQR5). Statistical analysis: Descriptive statistics. Chi² test or Fisher's exact test; Survival of treatment by Kaplan-Meier and log Rank. Multiple logistic regression. A p value <0.05 was considered significant. Results: We included 118 patients, 101 were women (85.6%), with a median age (m) of 56 years (IQR 49-64) and disease duration m 10 years (IQR 6-18). Thirty-five patients (29.7%) were smokers and 56 patients (47.5%) consumed coffee. Eighty-five patients (72%) received MTX orally. 43.2% presented AE associated with MTX, but only 20 patients (16.9%) had to discontinue MTX. Gastrointestinal intolerance was the most frequent AE (27.1%), followed by laboratory test abnormalities (12.7%). 86.6% of the patients presented an adherence ≥80%. The median cumulative survival of MTX treatment was 348 months (95% CI: 235-460.9). In the univariate and multivariate analysis, there was no association of survival of MTX with sociodemographic variables, disease characteristics, concomitant treatment, route of administration, coffee consumption nor level of adherence. Conclusions: In our cohort, adherence and survival of MTX treatment were good. The cumulative survival was almost 30 years. The presence of AE did not determine the suspension of treatment in most cases.


Assuntos
Artrite Reumatoide , Terapêutica , Metotrexato
8.
Rev. argent. reumatol ; 30(2): 33-35, jun. 2019. ilus, tab
Artigo em Espanhol | LILACS | ID: biblio-1041883

RESUMO

Abatacept es el primer agente biológico aprobado para el tratamiento de la Artritis Reumatoidea (AR) que actúa inhibiendo la co-estimulación de linfocitos T. Si bien se ha reportado su eficacia en psoriasis y artritis psoriásica, existen casos de psoriasis inducida por el fármaco como así también reactivación de las lesiones en pacientes previamente enfermos. Una mujer con antecedentes de AR en tratamiento con Abatacept endovenoso presentó máculas eritemato-escamosas y pruriginosas en toda la superficie corporal, clínica e histológicamente compatibles con psoriasis. La suspensión del tratamiento con Abatacept, ocasionó la desaparición de las lesiones cutáneas. Mas de 4 años después se encuentra en tratamiento con Rituximab sin haber vuelto a presentar compromiso cutáneo.


Abatacept is the first biological agent approved for the treatment of Rheumatoid Arthritis (RA) that acts blocking interaction of T lymphocytes. Although its efficacy in psoriasis and psoriatic arthritis has been reported, there are reports of drug induced psoriasis as well as reactivation of cutaneous lesions. A woman with a history of RA under treatment with Abatacept IV presented erythematous-scaly and pruritic macules on the entire body surface, clinically and histologically compatible with psoriasis. The suspension of treatment with Abatacept caused the disappearance of the cutaneous lesions. More than 4 years later he is in treatment with Rituximab without presenting cutaneous lesions.


Assuntos
Artrite Reumatoide , Psoríase , Abatacepte
9.
Rev. am. med. respir ; 19(2): 159-161, jun. 2019. ilus
Artigo em Espanhol | LILACS | ID: biblio-1041695

RESUMO

Caso clínico: Paciente de sexo masculino, de 72 años. Ingresa por un cuadro de disnea súbita mMRC 2-3, con progresión a disnea mMRC 4. Refiere tos crónica sin cambio en sus características. Niega fiebre. Antecedentes: Ex tabaquista (36 paquetes/año), con antecedentes de artritis reumatoidea, y fibrosis pulmonar. Examen físico: Saturación de oxígeno 88% aire ambiente, taquipneico. Con hipoventilación y crepitantes velcro hasta el tercio medio, bilaterales. Exámenes complementarios: Hemograma normal. La gasometría arterial revela alcalosis respiratoria compensada. La espirometría y los volúmenes pulmonares se encuentran dentro de los límites de referencia, se observa disminución severa de la capacidad de difusión pulmonar (DLCO). La tomografía computarizada torácica de alta resolución (TCAR) (Figuras 1 y 2) muestra enfisema en los lóbulos superiores, con fibrosis de predominio en lóbulos inferiores, no se observan signos indirectos de hipertensión pulmonar


Assuntos
Artrite Reumatoide , Fibrose Pulmonar , Enfisema
10.
Rev. argent. reumatol ; 30(1): 3-3, mar. 2019.
Artigo em Espanhol | LILACS | ID: biblio-1013374
11.
Rev. argent. reumatol ; 30(1): 16-21, mar. 2019. ilus, tab
Artigo em Espanhol | LILACS | ID: biblio-1013376

RESUMO

Recientemente, validamos el cuestionario Quality of Life-Rheumatoid Arthritis Scale (QOL-RA) y detectamos la presencia de algunas limitaciones. Por esta razón, con la autorización de la autora, cambiamos dos preguntas y desarrollamos una nueva versión en español: el QOL-RA II. Objetivo: Validar el QOL-RA II en una cohorte argentina de pacientes con Artritis Reumatoidea (AR). Material y métodos: Estudio de corte transversal. Se incluyeron pacientes ≥18 años de edad, con diagnóstico de AR según criterios ACR-EULAR 2010. Se consignaron datos sociodemográficos, comorbilidades, características clínicas y actividad de la enfermedad. Se administraron los cuestionarios EQ-5D-3L, QOL-RA II, HAQ-A y PHQ-9. A 20 pacientes se les re-administró el cuestionario a los 7 días de haber completado el primero para evaluar reproducibilidad. Análisis estadístico: Test T de Student, ANOVA, Chi². Correlación de Spearman. Alpha de Cronbach. Coeficiente de correlación intraclase. Regresión Logística Multinomial con modelo factorial completo. Regresión lineal múltiple. Resultados: Se incluyeron 430 pacientes, con un tiempo mediano (m) de evolución de 9 años (RIC: 4-16). La m del QOL-RA II fue 6,7 (RIC: 5,3-8). El tiempo promedio para completarlo fue de 1,7±0,57 minutos y para su cálculo de 12±1,7 segundos. Solo 9 (2,1%) pacientes no contestaron alguna pregunta. El cuestionario presentó excelente confiabilidad (α de Cronbach 0,97), reproducibilidad (CCI: 0,96) y buena correlación entre los diferentes ítems y el cuestionario total, sin evidencia de redundancia. QOL-RA II presentó además, buena correlación con EQ-5D-3L (Rho: 0,6), HAQ-A (Rho: 0,55) y PHQ-9 (Rho: 0,56) y moderada con los índices de actividad de la enfermedad DAS28-ERS (Rho: 0,38) y CDAI (Rho: 0,46). Se evidenció peor calidad de vida en aquellos pacientes que no realizaban actividad física (X 6,4±1,9 vs. 7±1,8, p <0,0001), en los desocupados (X 6,1±1,9 vs. 7±1,8, p <0,0001) y en los tabaquistas (X 6,2±1,7 vs. 6,7±1,9, p=0,03). Se observó una tendencia significativa a empeorar la calidad de vida a mayor actividad de la enfermedad. Ajustando por edad, sexo y tiempo de evolución de la enfermedad, las variables que se asociaron significativamente a peor calidad de vida fueron la desocupación, la mayor actividad de la enfermedad, la discapacidad funcional y la presencia de depresión. Conclusión: El QOL-RA II demostró buena validez de constructo, reproducibilidad. Fue fácil de completar y calcular. No se observó redundancia entre las preguntas ni influencia por la edad ni el tiempo de evolución de la enfermedad.


We have recently validated the Quality of Life-Rheumatoid Arthritis Scale (QOL-RA). We have found some limitations, that is why, with the author's permission, we have changed two questions and developed a new Spanish version, QOL-RA II. Objective: To validate the QOL-RA II in an Argentinean cohort of patients with Rheumatoid Arthritis (RA). Material and methods: Cross-sectional study. Patients ≥18 years old, with a diagnosis of RA according to ACR-EULAR 2010 criteria were included. Sociodemographic data, comorbidities, RA characteristics, disease activity current treatment were registered. Questionnaires were administered: EQ-5D-3L, QOL-RA, HAQ-A and PHQ-9. The QOL-RA II was re-administered in 20 patients to evaluate reproducibility. Statistical analysis: Student's T, ANOVA and Chi² tests. Spearman correlation. Cronbach's alpha. Reproducibility using ICC. Multinomial logistic regression with completed factorial model. Multiple linear regression. Results: 430 patients were included, with a median (m) disease duration of 8.9 years (IQR: 4-16). QOL-RA was m 6.6 (IQR: 5.3-8). Mean time to complete it was 1.7±0.57 minutes and to calculate it 12±17 seconds. Only 2.1% of the questionnaires presented missing answers. It showed very good reliability (Cronbach's alpha 0.97), reproducibility (ICC: 0.96) and good correlation between the different items and the total questionnaire, without evidence of redundancy. Besides, QOL-RA II presented good correlation with EQ-5D-3L (Rho: 0.6), HAQ-A (Rho: 0.55) and PHQ-9 (Rho: 0.56) and moderate with DAS28-ESR (Rho: 0.38) and CDAI (Rho: 0.46). Worse quality of life was observed in patients not doing physical activity (X 6.4±1.9 vs. 7±1.8, p <0.0001), unemployed (X 6.1±1.9 vs. 7±1.8, p <0.0001) and current smokers (X 6.2±1.7 vs. 6.7±1.9, p=0.03). Patients with higher disease activity had a significant poorer quality of life. Adjusting by age, sex and disease duration, unemployment, higher disease activity, disability and the presence of depression were independently associated to worse quality of life. Conclusions: QOL-RA II demonstrated good construct validity, reproducibility and reliability. It was easy to complete and calculate. There were no redundancy between questions and it was not influenced by age and disease duration.


Assuntos
Artrite Reumatoide , Qualidade de Vida , Inquéritos e Questionários
12.
Rev. argent. reumatol ; 30(1): 28-34, mar. 2019. graf, tab
Artigo em Espanhol | LILACS | ID: biblio-1013377

RESUMO

Objetivo: Este estudio se propone evaluar el cumplimiento del tratamiento farmacológico en pacientes con AR e identificar los factores que pueden afectar al mismo. Materiales y métodos: Estudio observacional, analítico, transversal. Se realizaron encuestas a 176 pacientes de la base de datos, seleccionados al azar de un centro privado especializado en Reumatología ubicado en el conurbano sur de la provincia de Buenos Aires (Instituto Médico CER - Quilmes). Entre septiembre de 2015 y julio de 2016 fueron realizadas de manera telefónica por voluntarios no médicos de la Fundación Articular entrenados a tal fin. Se utilizaron los cuestionarios BAM, CQR19 y se indagó la percepción del paciente sobre su grado de adhesión al tratamiento dividiéndolo en dos grupos: cumplimiento total o cumplimiento parcial/nulo. Se recabaron datos sociodemográficos, estado de enfermedad, tratamiento, comorbilidades y hábitos. Se utilizaron las siguientes pruebas estadísticas: ANOVA de un factor para evaluar diferencias en niveles medios de CQR19 y variables cualitativas; prueba de Brown-Forsythe para determinar asociación entre CRQ y diversas variables, correlación no paramétrica Rho de Spearman entre CQR19 y variables cuantitativas y regresión logística para explicar adherencia al tratamiento (CQR19 agrupada). Los datos fueron analizados usando el programa SPSS (versión 19.0). Resultados: El 85,8% eran mujeres y la edad promedio fue de 55,1 años. El 51,1% de los pacientes considera que su salud es buena con relación a la AR y el 40,9% considera que es regular. El tratamiento más frecuente fue MTX oral (79%). La monoterapia fue la modalidad terapéutica más referida (79,5%) y el tiempo medio de tratamiento es de 4,4 años. La actitud de los pacientes hacia los medicamentos mostró acuerdo en los 5 ítems que corresponden a la dimensión necesidad del BAM. El nivel de acuerdo-desacuerdo resultó más heterogéneo en los ítems de la dimensión preocupación. CQR19 mostró alto nivel de acuerdo en la mayor parte de los ítems positivos y alto nivel de desacuerdo en la mayor parte de los ítems negativos. Las únicas variables que se asociaron a mayor CQR fueron la presencia de comorbilidades (Brown-Forsythe=7,960; p=0,005) y medicación concomitante (Brown-Forsythe=7,529; p=0,007). También se encontró asociación significativa entre CRQ19 y tabaquismo (F=0,019; p=0,981). Se observó correlación significativa entre CQR y BAM Específico-Necesidad (Rho=0,379; p <0,001) y entre CQR y BAM Específico-Preocupación (Rho=-0,188; p=0,012). Se observó mayor adherencia cuando el paciente siente la necesidad de cumplir con la medicación (O.R.=1,342; p=0,012) y cuando menos preocupado está por la misma (O.R.=0,870; p=0,047). Detectamos menor cumplimiento del tratamiento en pacientes casados o que viven en pareja (Chi²=7,448; p=0,024) y con mayor nivel educativo (Chi²=6,313; p=0,043). Cuando se evalúa el cumplimiento de la medicación prescrita por indagación directa a los pacientes, el nivel de cumplimiento es más elevado. Conclusión: Se trata de una población con nivel moderado de adherencia. Mayor conciencia de necesidad de medicación y menor nivel de preocupación acerca de la misma generan mayor adherencia. Los pacientes sobreestiman el cumplimiento de la medicación cuando se los interroga de manera directa por lo cual es mandatorio utilizar otro método de evaluación. El mayor conocimiento de la adherencia de los pacientes con AR nos permitirá desarrollar herramientas que mejoren este aspecto a largo plazo.


Objective: This study aims to evaluate the compliance of pharmacological treatment in patients with RA and identify the factors that may affect it. Materials and methods: Observational, analytical and cross-sectional study. Surveys were conducted on 176 randomly selected patients from a private center specialized in Rheumatology located in the southern suburbs of the province of Buenos Aires (CER Medical Institute - Quilmes), between September 2015 and July 2016, by telephone by trained non-medical volunteers of the Articular Foundation. The BAM, CQR19 questionnaires were used and the patient's perception of their degree of adherence to the treatment was investigated, dividing it into two groups: total compliance or partial/no compliance. Sociodemographic data, disease status, treatment, comorbidities and habits were collected. The following statistical tests were used: one-way ANOVA to evaluate differences in mean levels of CQR19 and qualitative variables; Brown-Forsythe test to determine the association between CRQ and various variables, non-parametric Spearman's Rho correlation between CQR19 and quantitative variables and logistic regression to explain adherence to treatment (CQR19 grouped). The data was analyzed using the SPSS program (version 19.0). Results: 85.8% were women and the average age was 55.1 years. 51.1% of patients consider that their health is good in relation to RA and 40.9% consider it to be fair. The most frequent treatment was oral MTX (79%). Monotherapy was the most referred therapeutic modality (79.5%) and the mean treatment time is 4.4 years. The attitude of the patients towards the medicines showed agreement in the 5 items that correspond to the dimension of necessity of the BAM. The level of agreement-disagreement was more heterogeneous in the items of the concern dimension. CQR19 showed a high level of agreement in most of the positive items and a high level of disagreement in most of the negative items. The only variables that were associated with higher CQR were the presence of comorbidities (Brown-Forsythe=7.960, p=0.005) and concomitant medication (Brown-Forsythe=7.529, p=0.007). There was also a significant association between CRQ19 and smoking (F=0.019, p=0.981). Significant correlation was observed between CQR and BAM Specific-Necessity (Rho=0.379, p <0.001) and between CQR and BAM Specific-Concern (Rho=-0.188; p=0.012). Greater adherence was observed when the patient felt the need to comply with the medication (O.R.=1.342, p=0.012) and when least concerned about it (O.R.=0.870, p=0.047). We detected less compliance with treatment in married patients or those living with a partner (Chi²=7.448, p=0.024) and with a higher educational level (Chi²=6.313, p=0.043). When the compliance of the prescribed medication is evaluated by direct inquiry to the patients, the level of compliance is higher. Conclusion: It is a population with a moderate level of adherence. Greater awareness of the need for medication and a lower level of concern about it generate greater adherence. Patients overestimate medication compliance when they are interrogated directly, which is why it is mandatory to use another evaluation method. The greater knowledge of the adherence of patients with RA will allow us to develop tools that improve this aspect in the long term.


Assuntos
Artrite Reumatoide , Terapêutica , Adesão à Medicação
13.
Fisioter. Mov. (Online) ; 32: e003229, 2019. tab, graf
Artigo em Inglês | LILACS | ID: biblio-1039879

RESUMO

Abstract Introduction: Treatments for rheumatoid arthritis (RA) and osteoarthritis (OA) can reduce, modulate inflammation, and reduce deformities. Low-Level Laser Therapy is a biomodulator and may aid in the clinical picture of these conditions. Objective: To analyze the parameters most frequently used to determine the responses of patients with RA and OA in controlled and uncontrolled clinical trials. Method: This is a systematic review with search of articles in English, Portuguese and Spanish in PUBMED, SCOPUS, LILACS and Web of SCIENCE, of articles published between 2006 and 2018. MeSH terms were used. Inclusion criteria: evaluation of LLLT in the evaluations, evaluation and evaluation of the period, controlled and uncontrolled clinical trials, full publications. The base date of the energy dosimetry and the analysis of mean, median and mode of energy per point and energy per treatment. Results: Three articles on RA and 16 on OA were included in this study. Regarding dosimetry, it was one of the most recent of the pain, being this one with a greater energy dose. In OA, most of the articles presented are of importance, with variability in the dosage applied. Conclusion: There are several reports for patient studies purposes, mainly with doses of 6 J per point and 48 J. In the joints affected with OA and AR, it would be important to publish more scientific articles with better methodological quality and description of dosimetry.


Resumo Introdução: Os tratamentos para artrite reumatoide (AR) e osteoartrite (OA) devem diminuir dor, modular inflamação e diminuir deformidades. O LLLT é um biomodulador e pode auxiliar no quadro clínico destas. Objetivo: Analisar os parâmetros mais comumente utilizados para a diminuição das respostas de dor em pacientes com AR e OA em ensaios clínicos controlados e não controlados. Método: Trata-se de uma revisão sistemática com busca de artigos em inglês, português e espanhol na: PUBMED, SCOPUS, LILACS e Web of SCIENCE, entre 2006 a 2018. Foram utilizados os descritores MESH. Critérios de inclusão: avaliação da eficácia do LLLT nestas populações, verificação da dor antes e depois do tratamento, ensaios clínicos controlados e não controlados, publicados integralmente. Foi realizado o cálculo da dosimetria do laser e análise de média, mediana e moda da energia por ponto e energia por tratamento. Resultados: Incluídos neste estudo 3 artigos de AR e 16 de OA. Em relação à dosimetria, apenas um AR apresentou redução da dor, sendo este com a maior dose de energia. Já na OA, a maioria dos artigos apresentou diminuição da dor, e com variabilidade na dosagem aplicada. Alguns tiveram poucos parâmetros apresentados, tornando impossível calcular a dosimetria. Conclusão: há evidências científicas para reduzir a dor relatada em pacientes com OA de joelho, principalmente com doses de 6 J por ponto e 48 J aplicadas no tratamento diário. Para as outras articulações afetadas com OA e AR, seria importante a publicação de mais artigos científicos com melhor qualidade metodológica e descrição da dosimetria.


Resumen Introducción: Los tratamientos para la artritis reumatoide (AR) y la osteoartritis (OA) pueden reducirse, modular, encender y disminuir las deformidades. El LLLT es un biomodulador y puede auxiliar en el cuadro clínico de éstas. Objetivo: Analizar los parámetros más frecuentemente utilizados para determinar las respuestas de pacientes con AR y OA en ensayos clínicos controlados y no controlados. Método: Se trata de una revisión sistemática y la búsqueda de artículos en Inglés, portugués y español en: PubMed, SCOPUS, se utilizaron LILACS y Web of Science, entre 2006 y 2018. Los descriptores de malla. Criterios de inclusión: evaluación de la LLLT en las evaluaciones, evaluación y evaluación del período, ensayos clínicos controlados y no controlados, íntegramente. La fecha base de la dosimetría de energía y el análisis de media, media y moda de la energía por punto y energía por tratamiento. Resultados: Incluido en este estudio 3 artículos de AR y 16 de OA. En cuanto a la dosimetría, fue uno de los más recientes del dolor, siendo éste con una dosis mayor de energía. En la OA, la mayoría de los artículos presentados son de importancia, con la variabilidad en la dosificación aplicada. Se han tenido pocos pocos parámetros parámetros parámetros presentados presentados. Conclusión: hay una serie de informes para fines de estudios con pacientes, principalmente con dosis de 6 J por punto y 48 J. Las articulaciones afectadas con OA y AR, sería importante la publicación de más artículos científicos con mejor calidad metodológica y descripción de dosimetría.


Assuntos
Osteoartrite , Artrite Reumatoide , Terapia com Luz de Baixa Intensidade , Dor , Dosimetria
14.
Braz. J. Pharm. Sci. (Online) ; 55: e17240, 2019. tab, graf
Artigo em Inglês | LILACS | ID: biblio-1019531

RESUMO

Iguratimod (IGU, also known as T-614), a novel disease modifying antirheumatic drug intended to cure patients with rheumatoid arthritis (RA). The purpose of this study is to evaluate the effect of IGU on the pharmacokinetics of CYP2C9 probe drug diclofenac and its metabolite 4′-hydroxy diclofenac in vivo and in vitro. In in vivo experiments, 24 rats were randomly assigned to three groups consisting of the control group (Normal saline), low dose IGU group (10 mg/kg) and high dose IGU group (30 mg/kg). Blood samples were collected from orbital sinuses vein before 1 hour and serial times of giving diclofenac (15 mg/kg) to all the rats. Plasma concentration of diclofenac and its metabolite 4´-hydroxy diclofenac were assayed by high performance liquid chromatography. Pharmacokinetic parameters were assessed by Winnonlin 6.4 pharmacokinetic software. Moreover, in vitro studies were performed in recombinant human CYP2C9 yeast cell system. IGU at low dose showed no significant differences in the pharmacokinetic parameters of diclofenac and 4-hydroxy diclofenac in vivo when compared with control group (p>0.005). However, at the high dose of IGU, the pharmacokinetic parameters of 4´-hydroxy metabolite of diclofenac increase in half-life (T1/2) and mean area under the curve (AUC0→24), while a decrease in mean clearance (CL, mL/h/kg) and volume of distribution Vz (mL/kg). In addition, in in vitro study, high doses of IGU reduces the metabolism rate of diclofenac. IGU at high dose significantly increase the pharmacokinetics parameters of 4´-hydroxy diclofenac in rats. Additionally, it also showed the potent inhibitory effect on diclofenac metabolism in recombinant human CYP2C9 yeast cells.


Assuntos
Animais , Masculino , Feminino , Ratos , Diclofenaco/efeitos adversos , Citocromo P-450 CYP2C9 , Citocromo P-450 CYP2C9/farmacocinética , Anti-Inflamatórios/efeitos adversos , Artrite Reumatoide/classificação , Técnicas In Vitro
15.
Rev. Hosp. Clin. Univ. Chile ; 30(1): 33-42, 2019.
Artigo em Espanhol | LILACS | ID: biblio-1005576

RESUMO

Cardiovascular disease (CVD) is the most frequent cause of premature death according to data from the American Heart Association and World Health Organization. Incidence and prevalence are on the rise. Rheumatoid Arthritis (RA) is the most common autoimmune disease. It is a chronic and systemic disease characterized by articular involvement with deformity ranging from persistent pain to premature disability. CVD is the most frequent cause of death in RA patients, even more than in diabetes mellitus 2 or chronic kidney disease. Multiple CVD risk scales have been tested in order to obtain a more accurate prediction of premature death by stroke or myocardial infarction in RA patients. Most of the scales, even those adjusted including RA features like inflammation and antibodies titles, have failed to properly predict the real CVD risk. Individually, RA specific autoantibodies have been related with increased CVD risk and multiple mechanistic explanations have arisen, generating even a new concept called "Autoimmune Atheromatosis". Nevertheless, this association fails to give a full understanding of the accelerated and aggressive atheromatosis process that RA patients develop. New studies oriented to mechanistic explanations are necessary in order to develop new diagnostic targets and prevention strategies. (AU)


Assuntos
Artrite Reumatoide/tratamento farmacológico , Doenças Cardiovasculares , Comorbidade , Artrite Reumatoide/complicações
16.
Artigo em Espanhol | LILACS | ID: biblio-1102783

RESUMO

El abordaje terapéutico de pacientes con dos o más enfermedades autoinmunes es un verdadero desafío, especialmente cuando el tratamiento enfocado en una de ellas podría precipitar la progresión de la otra. Si bien la asociación de artritis reumatoidea (AR) con colangitis biliar primaria (CBP) no es tan frecuente, cuando coexisten, la utilización de metotrexato u otras drogas hepatotóxicas debe decidirse con cautela. Con la indicación más generalizada de las drogas biológicas modificadoras del curso de la AR (DMARb) han aparecido algunos reportes de pacientes con AR y CBP tratados con etanercept, infliximab, rituximab, tocilizumab y abatacept. Presentamos una serie de casos de 4 pacientes con AR y CBP que fueron tratados con DMARb. Nuestro reporte sería el primero en describir dos casos con golimumab para controlar la AR y el segundo en reportar un caso con adalimumab y otro con abatacept. Con rituximab, ya existen tres casos publicados. En ninguno de los pacientes de nuestra serie empeoraron los síntomas de CBP y, al contrario, en dos de ellos hubo mejoría de los parámetros bioquímicos. En conclusión, según lo observado y lo reportado en la literatura, el uso DMARb podría ser considerado en el caso de pacientes con AR activa que además padecen CBP


The therapeutic approach of patients with two or more autoimmune diseases is quite a challenge, especially when the treatment of one of them, can precipitate the progression of the other. Even though the association of rheumatoid arthritis (RA) and primary biliary cholangitis (PBC) is rare; when both coexist, the use of methotrexate and other hepatotoxic drugs should be used with caution. With a most widespread indication of biologic diseasemodifying antirheumatic drugs (bDMARDs) some reports of patients with RA and PBC treated with etanercept, infliximab, rituximab, tocilizumab and abatacept have been published. We report a case series that includes 4 patients with RA and PBC treated with bDMARDs. This is the first report to describe two cases in which golimumab was used to control RA and the second to report patients who received adalimumab and abatacept. Three cases of patients treated with rituximab have been published to date. None of the patients of our report suffered a progression of their PBC; matter in fact, two of them showed an improvement in their biochemical parameters. PBC symptoms did not get worse in any of the patients. On the contrary, laboratory parameters improved in two of the four patients. In conclusion, according to the literature reviewed and to our findings, the use of bDMARDs could be considered in RA patients with concomitant PBC


Assuntos
Artrite Reumatoide , Colangite
17.
Rio de Janeiro; s.n; 2019. 113 f p. graf, tab, fig.
Tese em Português | LILACS | ID: biblio-997864

RESUMO

A artrite reumatoide é uma doença inflamatória crônica com prevalência mundial estimada entre 0,5 e 1%, caracterizada por dor, edema e rigidez matinal nas articulações. A doença não controlada leva à destruição articular progressiva, causando perda da qualidade de vida e da capacidade funcional. A manutenção da capacidade envolve estar apto a realizar atividades básicas do cotidiano, envolvendo higiene pessoal, carregar objetos, vestir-se, alimentar-se e locomover-se. Limitações ou impossibilidade de realizar estas atividades implica em alguma incapacidade funcional - geralmente mensurada, na artrite reumatoide, por um dos componentes do Questionário de Avaliação de Saúde. Esta dissertação teve como objetivo geral analisar a variação da capacidade funcional medida pelo Questionário de Avaliação de Saúde ­ Índice de Incapacidade em pacientes com artrite reumatoide acompanhados ambulatorialmente por um ano e propor um modelo preditivo, em função de fatores sociodemográficos e clínicos. Os objetivos específicos foram: (i) avaliar quais variáveis, previamente reportadas na literatura, têm impacto sobre a capacidade funcional dos pacientes com artrite reumatoide de uma coorte nacional; (ii) construir um modelo preditivo próprio à realidade brasileira utilizando variáveis de fácil obtenção; e (iii) avaliar se há modificação de efeito pela interação entre atividade de doença e o tempo no estudo. Avaliamos 1111 pacientes com artrite reumatoide atendidos em 11 centros de referência para tratamento de doenças reumáticas vinculados ao Sistema Único de Saúde, com coleta de dados prospectiva. Utilizamos modelos lineares de efeitos mistos para avaliar a variação da capacidade funcional, mensurada pelo Questionário de Avaliação de Saúde ­ Índice de Incapacidade, nos dados coletados em três momentos ao longo de um ano. Esta análise revelou que, na população avaliada, sexo, status socioeconômico, dor articular, uso prévio de medicamentos imunobiológicos, atividade e tempo de doença estavam associados à variação da capacidade funcional, com capacidade explicativa de 37% de nosso modelo. Ao definir as variáveis a analisar a partir de um referencial teórico estruturado com a revisão de literatura, identificamos que nossos achados apresentaram pontos comuns com estudos realizados na Europa e América do Norte. Alguns destes achados foram: pior capacidade funcional em pacientes com mais dor e doença em atividade, em pacientes do sexo feminino e naqueles que tenham feito uso prévio de medicamento imunobiológico. Também foram relevantes as curvas em formato de J relacionadas com mais tempo de doença e pior status socioeconômico. Levantamos algumas hipóteses para os escores de incapacidade encontrados nesta população, como a adaptação dos pacientes às limitações com o avanço do tempo de doença e a percepção de que estas limitações seriam parte do envelhecimento normal. Apesar de construído a partir de uma população com mais de uma década de doença, nosso modelo incluiu variáveis comumente associadas ao componente reversível da incapacidade funcional, como dor e atividade de doença. Neste cenário, o melhor controle da doença traria benefícios aos pacientes, com recuperação de ao menos parte da capacidade funcional


Rheumatoid arthritis is an inflammatory chronic disease with estimated global prevalence of 0.5 ­ 1%, characterized by morning stiffness, joint pain and swelling. If not controlled, the disease leads to progressive joint destruction, decreasing quality of life and functional capacity. To maintain this capacity involves being able to perform basic daily life activities, such as those related with personal hygiene, to carry objects, to get dressed, to eat and to deambulate. Limitations or to be unable to perform these activities implies in at least some functional disability ­ usually measured, in rheumatoid arthritis patients, by one of the Health Assessment Questionnaire components. This dissertation's general aim was to analyze functional capacity variation, measured by the Health Assessment Questionnaire ­ Disability Index, in a Brazilian cohort of rheumatoid arthritis patients followed at outpatients clinics for a year and to create a predictive model as result of several demographic and clinical features. The specific aims were: (i) to evaluate which of the variables that were previously reported in the literature have impact on the functional capacity of RA patients in a Brazilian cohort; (ii) to build a predictive model adjusted to the Brazilian reality with variables of feasible acquisition; and (iii) to evaluate if there is effect modification due to the interaction between disease activity and length of time in the study. We evaluated 1111 rheumatoid arthritis patients followed at 11 reference treatment centers for rheumatic diseases, all pertaining to the Unified Health System ­ SUS, with prospective data collection. We applied linear mixed effects models to evaluate the variation in functional capacity, measured by Health Assessment Questionnaire ­ Disability Index, within the data collected at three time points along one year. This analysis revealed that, in the evaluated population, sex, socioeconomic status, joint pain, previous use of immunobiological drugs, disease duration and activity were associated with functional capacity variation, in a model with a 37% explanatory capacity. After defining which database variables to use from a theorical model structured with the literature review, we identified that our findings presented common aspects with studies from Europe and North America. A few of the findings were: decrease of functional capacity with pain and disease activity, in female patients and also in those with previously reported immunobiological use. Also relevant were the J-shaped curves related with longer disease duration and worse socioeconomic status. Some hypotheses for the functional capacity scores found were patient adaptability to physical limitations accrued with disease duration and perception that those limitations would be part of a normal ageing process. Though built with data from a population with more than a decade of disease duration, our model included variables commonly associated with the reversible component of functional disability, such as pain and disease activity. In this scenario, tighter control of disease activity would benefit patients and bring the possibility of regaining, at least partially, their functional capacity


Assuntos
Humanos , Artrite Reumatoide/epidemiologia , Qualidade de Vida , Reumatologia , Sistema Único de Saúde , Brasil , Estudos de Coortes , Pessoas com Deficiência , Limitação da Mobilidade
18.
Rev. argent. reumatol ; 29(4): 14-19, dic. 2018. ilus, tab
Artigo em Espanhol | LILACS | ID: biblio-1003292

RESUMO

En nuestro país existen pocos datos acerca de los patrones de tratamiento y la sobrevida de las Drogas Modificadoras de la Artritis Reumatoidea biológicas (DMARb) en pacientes con Artritis Reumatoidea (AR). El objetivo de nuestro estudio fue estimar la sobrevida del 1° y 2° agente biológico, determinar sus causas de suspensión y evaluar factores que influyan en la sobrevida de estos agentes. Material y métodos: Se realizó un estudio multicéntrico retrospectivo. Se incluyeron pacientes ≥18 años de edad que cumplieran con criterios ACR/EULAR 2010 para AR y que iniciaron su 1° y/o 2° DMARb entre 01/2006 y 06/2017, la recolección de datos se realizó mediante la revisión de historias clínicas. Se consignaron variables sociodemográficas y clínicas. Resultados: Se incluyeron 347 pacientes con edad mediana de 57,8 años, 89,6% mujeres, 96,5% tenían Factor Reumatoideo (FR) positivo. El 53,9% de los pacientes discontinuaron el tratamiento con la 1°DMARb, treinta y ocho pacientes (41,3%) discontinuaron el 2° DMARb. La causa más frecuente de suspensión del primer biológico fue la falta de provisión, mientras que la del segundo biológico fue la ineficacia. Las supervivencias medianas fueron: para la 1° DMARb 31 meses (IC 95%: 21,8-40,1) y para 2° DMARb 11 meses (IC 95%: 4-17,9), no observamos diferencias significativas en la supervivencia entre los distintos agentes, los factores independientemente asociados a menor supervivencia del 1° DMARb fueron el tabaquismo y menor edad y del 2° DMARb fue haber discontinuado el primer agente biológico debido a evento adverso. Conclusión: Las supervivencias medianas del 1° DMARb y del 2° DMARb fueron 2,6 años y menor a 1 año, respectivamente. A diferencia de otras cohortes de países desarrollados, la causa más frecuente de suspensión del primer biológico fue la falta de provisión de la medicación por parte del pagador, mientras que la del segundo biológico fue la ineficacia.


In our country there are few data about the treatment patterns and the survival of the Biologic Disease Modifying Antirheumatic Drugs (bDMARD) in patients with Rheumatoid Arthritis (RA). The objective of our study was to evaluate the survival of the 1st and 2nd biological agent, determine the causes of suspension and factors that influence on the survival of these agents. Material and methods: A retrospective multicenter study was conducted. We included patients ≥18 years of age who met the ACR/EULAR 2010 criteria for RA and who started in 1st and/or 2nd bDMARD between 01/2006 and 06/2017, the data collection was done by reviewing clinical charts The sociodemographic and clinical variables were recorded. Results: We included 347 patients with a median age of 57.8 years, 89.6% women, 96.5% had positive Rheumatoid Factor (RF). 53.9% of patients discontinued treatment with 1st bDMARD, thirty-eight patients (41.3%) discontinued the 2nd bDMARD. The most frequent cause of suspension of the first biological was the lack of provision, while the second biological was inefficacy. The median survivals were: for the 1st bDMARD 31 months (95% CI: 21.8-40.1) and for the 2nd bDMARD 11 months (95% CI: 4-17.9), we did not observe significant differences in survival between the different agents. The independent factors associated with lower survival of the 1st bDMARD were smoking and lower age and the 2nd bDMARD was to have discontinued the first biological agent due to an adverse event. Conclusion: The median survivals of the 1st bDMARD and the 2nd bDMARD were 2.6 years and less than 1 year, respectively. Unlike other cohorts of developed countries the most frequent cause of suspension of the first biological was the lack of provision of the drug by the payer, while the second biological was inefficacy.


Assuntos
Artrite Reumatoide , Fatores Biológicos
19.
Rev. argent. reumatol ; 29(3): 48-49, set. 2018.
Artigo em Espanhol | LILACS | ID: biblio-980212

RESUMO

En los últimos años, numerosas publicaciones ponderaron el uso de la US en el manejo diario de los pacientes con Artritis Reumatoidea (AR). Sin embargo, existe una tendencia actual de poner en dudas las diferentes posibilidades que brinda esta técnica, basados en algunas publicaciones, fortaleciendo el manejo clínico como principal sostén de nuestra práctica diaria


Assuntos
Artrite Reumatoide , Ultrassonografia
20.
Medicina (Ribeiräo Preto) ; 51(3): 203-206, jul.-set. 2018.
Artigo em Português | LILACS | ID: biblio-979670

RESUMO

A artrite reumatoide (AR) é uma doença de natureza autoimune, inflamatória, sistêmica e crônica, cuja característica clínica principal é a inflamação das articulações. Na sua apresentação habitual, o acometimento visceral ocorre após a instalação do quadro articular. O envolvimento pulmonar pode aparecer como derrame pleural, sendo este um evento incomum quando se apresenta como primeira manifestação da doença. Neste relato de caso, apresentamos um paciente do sexo masculino, de 52 anos diagnosticado posteriormente com Artrite Reumatoide, cuja manifestacão inicial foi o derrame pleural, demonstrando um desafio diagnóstico. (AU)


Rheumatoid Arthritis (RA) is a systemic autoimmune disease whose main clinical characteristic is persistent joint inflammation. In its usual presentation, the visceral involvement occurs after the articular one. Pulmonary involvement may appear as a pleural effusion, which is an unusual event as the first manifestation of the disease. In this case report, we present a 52-year-old male patient diagnosed with Rheumatoid Arthritis, whose initial manifestation was pleural effusion, demonstrating a diagnostic challenge. (AU)


Assuntos
Humanos , Masculino , Pessoa de Meia-Idade , Derrame Pleural , Artrite Reumatoide , Reumatologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA